MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31.

Income Overview

Net Income
-$190,528,000
EPS
-$0.87
Unit: Dollar

Income Statement
2025-12-31
Collaboration revenue - related party
0
Research and development
150,152,000
General and administrative
56,781,000
Impairment of long-lived asset
2,382,000
Total operating expenses
209,315,000
Loss from operations
-209,315,000
Interest and other income, net
19,289,000
Interest expense
1,075,000
Other income (expense), net
215,000
Total other income (expense), net
18,429,000
Loss before income taxes
-190,886,000
Tax benefit at federal statutory rate
-40,086,000
Research tax credits
1,783,000
Change in valuation allowance
35,414,000
Stock-based compensation
6,280,000
Other
175,000
Other adjustments
0
Income tax expense
0
Net loss
-190,886,000
Net unrealized gain on available-for-sale investments
358,000
Net comprehensive loss
-190,528,000
Basic EPS
-0.87
Diluted EPS
-0.87
Basic Average Shares
220,622,669
Diluted Average Shares
220,622,669
Unit: Dollar.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net comprehensiveloss-$190,528,000 Net unrealized gainon...$358,000 Net loss-$190,886,000 Interest and otherincome, net$19,289,000 Other income(expense), net$215,000 Loss before incometaxes-$190,886,000 Total other income(expense), net$18,429,000 Interest expense$1,075,000 Loss from operations-$209,315,000 Total operatingexpenses$209,315,000 Research and development$150,152,000 General andadministrative$56,781,000 Impairment of long-livedasset$2,382,000

Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics, Inc. (ALLO)